Stockreport

Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion [Seeking Alpha]

Relay Therapeutics, Inc.  (RLAY) 
PDF Investing Group Leader Follow Play 19min Summary Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + f [Read more]